Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
-
REGULATORY Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
-
BUSINESS IBM Leads Development of Integrated Drug Supply Database for Wholesaler Reps, Pharmacists
October 18, 2023
-
REGULATORY AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
-
REGULATORY Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
-
REGULATORY MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
-
BUSINESS Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
-
REGULATORY MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
-
REGULATORY Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
October 12, 2023
-
ACADEMIA G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
-
ORGANIZATION Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
-
REGULATORY Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
-
ORGANIZATION Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
-
BUSINESS Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
-
REGULATORY As Copay Debate Picks Up Steam, MHLW Floats 4 Ideas for Coverage Reform
October 2, 2023
-
REGULATORY Japan Seeking Solutions as Lab Monkey Shortage, Price Surge Threaten to Stymie Drug Development
October 2, 2023
-
REGULATORY Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…